Sarepta Therapeutics Inc
$ 15.93
-2.81%
05 Aug - close price
- Market Cap 1,730,394,000 USD
- Current Price $ 15.93
- High / Low $ 16.75 / 15.82
- Stock P/E 45.53
- Book Value 14.26
- EPS 0.36
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE 0.05 %
- 52 Week High 25.32
- 52 Week Low 14.68
About
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$22.17
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-02-25 | 2025-11-03 | 2025-08-06 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-01 | 2024-02-28 | 2023-11-01 |
| Reported EPS | None | 3.16 | -3.58 | -0.13 | 2.02 | -3.42 | 1.9 | 0.62 | 0.44 | 0.73 | 0.47 | 0.37 |
| Estimated EPS | 0.34 | 1.05 | -1.05 | -0.37 | 1.16 | -0.65 | 2.0603 | 0.37 | 0.47 | 0.41 | 0.01 | -0.49 |
| Surprise | 0 | 2.11 | -2.53 | 0.24 | 0.86 | -2.77 | -0.1603 | 0.25 | -0.03 | 0.32 | 0.46 | 0.86 |
| Surprise Percentage | None% | 200.9524% | -240.9524% | 64.8649% | 74.1379% | -426.1538% | -7.7804% | 67.5676% | -6.383% | 78.0488% | 4600% | 175.5102% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.34 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SRPT
2026-08-05 14:45:56
Sarepta Therapeutics is facing an FDA clinical hold on its Duchenne muscular dystrophy (DMD) therapy, Elevidys, due to safety concerns over acute liver failure, even as the global DMD market is projected to reach US$62.13 billion by 2030. Despite the hold, Sarepta has five other FDA-approved DMD treatments and a pipeline focused on genetic medicines for rare diseases, including new CEO Michael Severino's equity awards tied to long-term performance. Analyst opinions on the stock are divided, with some maintaining Outperform ratings while others have downgraded or reiterated Sell ratings due to the safety issues and demand uncertainty.
2026-08-05 13:45:56
Sarepta Therapeutics is poised to release its second-quarter earnings, with investors keenly observing the performance of its gene therapy ELEVIDYS under new CEO Michael Severino. The company faces scrutiny over whether ELEVIDYS sales can stabilize after a recent decline and safety concerns, impacting market sentiment and analyst ratings. The earnings call will provide the first opportunity for investors to hear Severino's plans for addressing challenges and driving growth.
2026-08-04 17:52:30
Sarepta Therapeutics Inc is projected to report earnings of 26 cents per share. This information is based on an earnings preview from Refinitiv, indicating upcoming financial disclosures for the company.
2026-07-31 16:10:11
Vanguard Portfolio Management LLC has disclosed an 8.05% beneficial ownership stake in Sarepta Therapeutics Inc. (SRPT) through an amended Schedule 13G filing. As of June 30, 2026, Vanguard beneficially owns 8,499,421 shares, holding sole voting power over 121,951 shares and sole dispositive power over all 8,499,421 shares. This passive investment is held on behalf of various affiliated entities and managed accounts, with no single individual having more than a 5% interest within these holdings.
2026-07-31 06:11:14
Michael Severino, M.D., has been appointed as the new Chief Executive Officer of Sarepta Therapeutics, a biopharmaceutical company specializing in precision genetic medicine for rare diseases. He succeeds Doug Ingram, who is retiring but will remain in an advisory role. Severino brings extensive experience from Tessera Therapeutics, AbbVie, and Amgen, and is expected to lead Sarepta in expanding its pipeline beyond Duchenne muscular dystrophy into other muscle, central nervous system, and cardiac diseases.
